GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline, with a price target of £14.50. The company’s shares closed yesterday at p1,402.50. Take advantage of ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.48. The company’s shares closed today at p1,344.00. Take advantage of TipRanks Premium ...

Considering GlaxoSmithKline's $105.74 billion in total assets, the debt-ratio is at 0.38. Generally speaking, a debt-ratio more than one means that a large portion of debt is funded by assets.

Health Sanofi, GlaxoSmithKline set to start Phase 3 trials for COVID-19 vaccine after earlier setback In December, companies said early trials showed 'insufficient' immune response in older adults ...

Canada has had a deal with GlaxoSmithKline for influenza vaccines since 2001. The new agreement, which took effect July 1, was announced at GSK Canada in Quebec City, which employs 900 people.

GlaxoSmithKline has been implicated in a bribery scandal involving its sales representatives in China and paid a $3-billion US fine in the U.S. for marketing drugs for unapproved uses and ...